Literature DB >> 10068714

Gout and hyperuricemia.

M D Harris1, L B Siegel, J A Alloway.   

Abstract

Gout is a condition characterized by the deposition of monosodium urate crystals in the joints or soft tissue. The four phases of gout include asymptomatic hyperuricemia, acute gouty arthritis, intercritical gout and chronic tophaceous gout. The peak incidence occurs in patients 30 to 50 years old, and the condition is much more common in men than in women. Patients with asymptomatic hyperuricemia do not require treatment, but efforts should be made to lower their urate levels by encouraging them to make changes in diet or lifestyle. Acute gout most commonly affects the first metatarsal joint of the foot, but other joints are also commonly involved. Definitive diagnosis requires joint aspiration with demonstration of birefringent crystals in the synovial fluid under a polarized light microscope. Treatment includes nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, corticosteroids and analgesics. In patients without complications, NSAID therapy is preferred.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10068714

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  42 in total

1.  Identification of low-frequency variants associated with gout and serum uric acid levels.

Authors:  Patrick Sulem; Daniel F Gudbjartsson; G Bragi Walters; Hafdis T Helgadottir; Agnar Helgason; Sigurjon A Gudjonsson; Carlo Zanon; Soren Besenbacher; Gyda Bjornsdottir; Olafur T Magnusson; Gisli Magnusson; Eirikur Hjartarson; Jona Saemundsdottir; Arnaldur Gylfason; Adalbjorg Jonasdottir; Hilma Holm; Ari Karason; Thorunn Rafnar; Hreinn Stefansson; Ole A Andreassen; Jesper H Pedersen; Allan I Pack; Marieke C H de Visser; Lambertus A Kiemeney; Arni J Geirsson; Gudmundur I Eyjolfsson; Isleifur Olafsson; Augustine Kong; Gisli Masson; Helgi Jonsson; Unnur Thorsteinsdottir; Ingileif Jonsdottir; Kari Stefansson
Journal:  Nat Genet       Date:  2011-10-09       Impact factor: 38.330

2.  Fluorescence and electrochemical recognition of nucleosides and DNA by a novel luminescent bioprobe Eu(III)-TNB.

Authors:  Hassan A Azab; E M Mogahed; F K Awad; R M Abd El Aal; Rasha M Kamel
Journal:  J Fluoresc       Date:  2012-05       Impact factor: 2.217

3.  Digit-Threatening Severe Tophaceous Gout.

Authors:  Brandon Kuiper; Paul Aronowitz
Journal:  J Gen Intern Med       Date:  2016-06       Impact factor: 5.128

Review 4.  The distribution of urate deposition within the extremities in gout: a review of 148 dual-energy CT cases.

Authors:  Paul I Mallinson; Adrian C Reagan; Tyler Coupal; Peter L Munk; Hugue Ouellette; Savvas Nicolaou
Journal:  Skeletal Radiol       Date:  2013-12-12       Impact factor: 2.199

5.  Spondyloarthritis: a gouty display.

Authors:  Preetam Gongidi; Shawn Gough-Fibkins
Journal:  J Radiol Case Rep       Date:  2010-05-01

Review 6.  The radiographic and MRI features of gout referred as suspected soft tissue sarcoma: a review of the literature and findings from 27 cases.

Authors:  Neil Upadhyay; Asif Saifuddin
Journal:  Skeletal Radiol       Date:  2014-09-24       Impact factor: 2.199

7.  Longitudinal transition trajectory of gouty arthritis and its comorbidities: a population-based study.

Authors:  Chien-Fang Huang; Ju-Chi Liu; Hui-Chuan Huang; Shao-Yuan Chuang; Chang-I Chen; Kuan-Chia Lin
Journal:  Rheumatol Int       Date:  2016-12-21       Impact factor: 2.631

8.  Pyrazinamide-induced hyperuricemia.

Authors:  Antony Q Pham; Anh Doan; Matt Andersen
Journal:  P T       Date:  2014-10

9.  Hypouricemic actions of exopolysaccharide produced by Cordyceps militaris in potassium oxonate-induced hyperuricemic mice.

Authors:  Li Ma; Song Zhang; Ying Yuan; Jianhua Gao
Journal:  Curr Microbiol       Date:  2014-08-03       Impact factor: 2.188

10.  Urinary L-type fatty acid-binding protein can reflect renal tubulointerstitial injury.

Authors:  Tamami Tanaka; Kent Doi; Rui Maeda-Mamiya; Kousuke Negishi; Didier Portilla; Takeshi Sugaya; Toshiro Fujita; Eisei Noiri
Journal:  Am J Pathol       Date:  2009-03-05       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.